logo
Red Meat Tied to High RA Risk; Fruits and Veggies Protective

Red Meat Tied to High RA Risk; Fruits and Veggies Protective

Medscape16-07-2025
TOPLINE:
The risk for developing rheumatoid arthritis (RA) rose with a high intake of red and processed meat vs fruits and vegetables in a case-control study.
METHODOLOGY:
The risk of developing RA based on dietary habits was explored in a Swedish nested case-control study within a prospective study conducted between January 1991 and September 1996 (n = 28,098).
Diet was assessed at baseline using a 7-day menu book, a 168-item questionnaire, and an interview lasting 45-60 minutes, and each RA patient was matched to four control individuals for analysis.
Compliance with the 2015 Swedish Dietary Guidelines for intake of fiber, fruits and vegetables, fish/shellfish, added sugars, and red or processed meat was scored and categorized as low, moderate, or high.
Data from registries and validated electronic medical records identified RA incidence through December 2016; data on rheumatoid factor and anticyclic citrullinated peptide antibody were also retrieved.
TAKEAWAY:
A total of 305 incident cases of RA were identified (76.1% women; 66.9% seropositive), with a mean age of 56.8 years at baseline and an average 12-year interval until diagnosis.
Consuming < 500 g/wk of red and processed meat (adjusted odds ratio [aOR], 0.60; 95% CI, 0.38-0.97) and ≥ 400 g/d of vegetables and fruits (aOR, 0.64; 95% CI, 0.43-0.94) significantly reduced the odds of developing RA.
Lower odds of developing RA were linked to fruits and vegetables (aOR per SD, 0.70; 95% CI, 0.57-0.87) and fiber (aOR per SD, 0.80; 95% CI, 0.64-0.99) vs higher odds with red and processed meat (aOR per SD, 1.31; 95% CI, 1.07-1.59).
Adhering to intake guidelines for all food types was linked to a lower risk for seropositive RA; higher odds were linked to higher consumption of red and processed meat (aOR, 3.43; 95% CI, 1.69-6.96).
IN PRACTICE:
'[The study] findings suggest a dose-response relationship between red/processed meat intake and the risk of seropositive, but not seronegative, RA. This study helps to improve our understanding of the effects of dietary components in RA development, particularly for red and processed meats, but the exact mechanisms behind our findings need further investigation,' the authors concluded.
SOURCE:
This study was led by Rebecka Bäcklund, Lund University, Malmö, Sweden. It was published online on July 10, 2025, in Annals of the Rheumatic Diseases.
LIMITATIONS:
The diet was assessed only at baseline. Data were retrieved from a study that examined the association between diet and cancer, which may have introduced selection bias. Dietary guidelines, especially regarding meat intake, may have changed over time.
DISCLOSURES:
This study received support from the Swedish Rheumatism Association, the Gustav V 80-year fund, the Greta and Johan Kock foundation, and others. The authors declared having no conflicts of interest.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Fast Five Quiz: Asthma Control and Long-term Outcomes
Fast Five Quiz: Asthma Control and Long-term Outcomes

Medscape

time9 minutes ago

  • Medscape

Fast Five Quiz: Asthma Control and Long-term Outcomes

Learn more about asthma control guidance. The GINA report notes that a history of one or more asthma exacerbations within the previous year is a well-established risk factor for future exacerbations, regardless of current symptom control. According to the same report, additional risk factors that similarly raise the risk for asthma flare-ups, regardless of how well symptoms are managed, include low socioeconomic status, poor adherence to medication, incorrect inhaler technique, reduced forced expiratory volume in one second, active smoking habit, and increased blood eosinophil counts. Thrombocytopenia, low oxygen saturation at rest, and alcohol use disorder are not among the risk factors for asthma exacerbations that are independent of symptom control. Learn more about working with patients to set and achieve long-term goals of asthma management. The latest GINA report encourages healthcare providers to assess asthma symptom control at every opportunity, including during routine prescribing and dispensing. The report emphasizes the importance of directed questioning, given symptom frequency and severity and treatment goals can significantly differ between patients and other current recommendations. Frequency of asthma symptoms, night waking, and short-acting beta-agonist use for symptom relief are some suggested question topics included in the GINA report. Learn more about asthma workup. The GINA report lists three integral facets of impactful asthma self-management instruction: a written action plan delineating recognition and response to worsening asthma, symptom and/or PEF self-monitoring, and regular review by a healthcare provider. Self-management that includes a written action plan is associated with reduced emergency department visits and hospitalizations. Although patients might find PEF monitoring helpful in certain circumstances, such as after an exacerbation or change in treatment, no specific frequency is endorsed. Self-adjustment of medications is not a required part of guided asthma self-management. No significant difference in self-management effectiveness has been identified whether the patient self-adjusts medication or if changes are made by a healthcare provider. While regular review by a clinician is an essential factor in asthma self-management education, the exact interval of these reviews is not specified. Learn more about control-based asthma management. In the latest GINA report, patients' establishing goals for their asthma and treatments is a part of disease assessment and control during management. This can help patients achieve optimal long-term asthma outcomes. Physician changes, medication dependency, and activity level modifications can be part of long-term control of asthma, but they greatly depend and vary based on the patient, their goals, and their treatment plan and are not always recommended. Learn more about long-term goals of asthma management. Editor's Note: This article was created using several editorial tools, including generative AI models, as part of the process. Human review and editing of this content were performed prior to publication. Lead image: Science Source

ImmunityBio's (IBRX) ANKTIVA Gets Approved by UK's Medicines and Healthcare Regulatory Agency
ImmunityBio's (IBRX) ANKTIVA Gets Approved by UK's Medicines and Healthcare Regulatory Agency

Yahoo

time38 minutes ago

  • Yahoo

ImmunityBio's (IBRX) ANKTIVA Gets Approved by UK's Medicines and Healthcare Regulatory Agency

ImmunityBio, Inc. (NASDAQ:IBRX) is one of the . On July 8, ImmunityBio, Inc. (NASDAQ:IBRX) announced that the UK's Medicines and Healthcare products Regulatory Agency has approved ANKTIVA with Bacillus Calmette-Guérin for treating certain bladder cancer patients. This is significant as it marks the first approval for the company outside of the United States of America. Moreover, the drug is a first-in-class IL-15 agonist, which works by activating and multiplying immune cells, specifically NK cells and T cells that help the body fight cancer. A technician analyzing natural killer cells, as part of an immune system study and research into therapeutical agents. In addition, clinical studies have shown strong results as some patients maintained a complete response for over 47 months at the last review. ImmunityBio, Inc. (NASDAQ:IBRX) is a biopharmaceutical company that develops therapies and vaccines that boost the immune system to fight cancer and infectious diseases. While we acknowledge the potential of IBRX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)
OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)

Yahoo

time38 minutes ago

  • Yahoo

OPKO Health's (OPK) Oral GLP-2 Analog Selected for a Poster Presentation in Collaboration with Entera Bio (ENTX)

OPKO Health, Inc. (NASDAQ:OPK) is one of the . On July 8, OPKO Health, Inc. (NASDAQ:OPK) in collaboration with Entera Bio Ltd. (NASDAQ: ENTX) announced the selection of their Oral GLP-2 Analog for a poster presentation at the 47th European Society for Clinical Nutrition & Metabolism Congress. This new therapy is a first in class and combines OPKO Health, Inc.'s (NASDAQ:OPK) long-acting GLP-2 agonist with Entera's N-Tab technology. The display will be in the Forum Hall Foyer 3, focusing on liver and gastrointestinal tract topics. The therapy treats short bowel syndrome, which is a condition where patients struggle to absorb nutrients due to a damaged or shortened intestine. Currently, the only approved treatment is GATTEX, which requires patients to inject themselves once a day. The oral GLP-2 tablet could change this. It aims to provide the same benefits without painful injections. This format may improve patient compliance and comfort. A doctor in scrubs discussing a patient's test results with a small group of concerned family members. OPKO Health, Inc. (NASDAQ:OPK) is an international biopharmaceutical company that develops and sells medicines, including human growth hormone and treatments for kidney disease. While we acknowledge the potential of OPK as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock. READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now. Disclosure: None. This article is originally published at Insider Monkey. Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store